Price
CHART BY
Frequently asked questions
What is Immunitybio's market capitalization?
The market capitalization of Immunitybio is $2.46B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Immunitybio?
Immunitybio's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.493. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Immunitybio's stock?
Currently, 5 analysts cover Immunitybio's stock, with a consensus target price of $10.20. Analyst ratings provide insights into the stock's expected performance.
What is Immunitybio's revenue over the trailing twelve months?
Over the trailing twelve months, Immunitybio reported a revenue of $56.60M.
What is the EBITDA for Immunitybio?
Immunitybio's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$269.07M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Immunitybio?
Immunitybio has a free cash flow of -$356.66M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Immunitybio have, and what sector and industry does it belong to?
Immunitybio employs approximately 680 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Immunitybio's shares?
The free float of Immunitybio is 98.33M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $2.46B
- EPS (TTM)
- -$0.493
- Free Float
- 98.33M
- Revenue (TTM)
- $56.60M
- EBITDA (TTM)
- -$269.07M
- Free Cashflow (TTM)
- -$356.66M
Pricing
- 1D span
- $2.553$2.62
- 52W span
- $1.835$7.47
Analyst Ratings
The price target is $10.20 and the stock is covered by 5 analysts.
Buy
5
Hold
0
Sell
0
Information
ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.
- Employees
- 680
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- Primary Ticker
- IBRX
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet